Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome

Table 1

Intravitreal injections rate and the endophthalmitis rate in two medical centers during the study period.

Agents	Anti-VEGF agents				Steroidal agents			Total
	Bevacizumab	Ranibizumab	Aflibercept	All	Triamcinolone acetonide injectable suspension	Dexamethasone intravitreal implant	All
Number of injections	22397	10840	17570	50807	47	502	549	51356
Relative injection rate	43.6%	21.1%	34.2%	98.9%	0.1%	1.0%	1.1%	100.0%
Endophthalmitis events	10	0	11	21	1	1	2	23
Endophthalmitis rate	0.045%	0.000%	0.063%	0.041%	2.128%	0.199%	0.364%	0.045%

()  = 0.025 for steroidal agents in comparison to anti-VEGF agents;  = 0.037 for bevacizumab in comparison to ranibizumab;  = 0.09 for aflibercept in comparison to ranibizumab;  = 0.437 for aflibercept in comparison to bevacizumab;  = 0.164 for triamcinolone acetonide injectable suspension in comparison to dexamethasone intravitreal implant.